Mark Dirnberger
Neuromusculoskeletal Medicine & OMM · Mansfield, TXNPI 1841366465
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,805 of the $8,066 with a category attached, or 84.4%. It is spread thinly across 55 manufacturers, the largest accounting for just 15.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $2,301 and has fallen 73.1% since, to $619 in 2025.
Across 399 payments — averaging $20.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biohaven Pharmaceuticals, Inc.$1K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
- Scilex Pharmaceuticals Inc.$892
- Amgen$605
- Collegium Pharmaceutical, Inc.$564
- AbbVie$452
- plus $3K from 49 others
Across 1 payment — averaging $150.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Indivior Inc.$150
What the payments were for
- Consulting fees$1,20015%
- Travel & lodging$400%
- Food & beverage$6,80584%
- Education$210%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NURTEC ODT$1,200
- Prolate$418
- ZTLido$219
- Nalocet$105
How this compares
Too few neuromusculoskeletal medicine & omm providers in Texasto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 1,251 | $49,931 |
| Xtampza ErOxycodone Myristate | 82 | $47,771 |
| NucyntaTapentadol Hcl | 20 | $28,420 |
| Nucynta ErTapentadol Hcl | 25 | $25,565 |
| Nurtec OdtRimegepant Sulfate | 11 | $20,663 |
| Oxycodone Hcl | 480 | $15,148 |
| Morphine Sulfate ErMorphine Sulfate | 387 | $12,650 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 278 | $11,576 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 95 | $11,388 |
| MovantikNaloxegol Oxalate | 22 | $9,679 |
| Emgality PenGalcanezumab-Gnlm | 11 | $7,817 |
| Diclofenac Sodium | 98 | $7,736 |
| Oxymorphone Hcl ErOxymorphone Hcl | 12 | $7,679 |
| Gabapentin | 509 | $7,355 |
| ZtlidoLidocaine | 15 | $5,669 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Xtampza Er, Nucynta, Nucynta Er | $564 | $101,756127 claims |
| PfizerNurtec Odt | $116 | $20,66311 claims |
| Hikma Pharmaceuticals USABuprenorphine-Naloxone, Morphine Sulfate | $42 | $12,505121 claims |
| Scilex Pharmaceuticals Inc.Ztlido | $892 | $5,66915 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few neuromusculoskeletal medicine & omm providers in Texason file to place this against a meaningful peer group, so we don't.
Other neuromusculoskeletal medicine & omm in Mansfield
- George SchwartzeWaco$10K
- Alejandro BetancourtHarlingen$4K
- Brett PicciottiGranbury$3K
- Kyle AllanAustin$622
- Marissa ZajacFort Worth$470
- Gregory DottDallas$300
- Gregory CoxFort Worth$93
- Richard DombroskiFort Worth$86
- Cheryl HowardHouston$82
- Aaron BooneFort Worth$75
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.